Urgent Evaluation and Management of Severe Virilization

Risk Stratification and Immediate Imaging

• Severe virilization (clitoromegaly, deep voice, male‑pattern muscle mass, male‑pattern alopecia, breast atrophy) mandates urgent pelvic ultrasound and adrenal CT to rule out an androgen‑secreting tumor, which accounts for > 50 % of androgen‑excess cases and > 50 % of those tumors are malignant. 1
• Any virilization sign indicates massive androgen production and requires immediate endocrine assessment. 1
• Total testosterone > 200 ng/dL is a strong indicator of an androgen‑secreting tumor and justifies urgent pelvic ultrasound and adrenal CT. 1
• Rapid onset of hyperandrogenic signs over weeks‑to‑months should trigger immediate imaging to exclude neoplasia. 1
• A palpable abdominal or pelvic mass on physical exam mandates urgent imaging. 1

Essential Biochemical Work‑up (fasting, morning)

• DHEAS > 600 µg/dL (≈ 16 000 nmol/L) suggests an adrenal adenoma and should prompt urgent abdominal CT. 1
• 17‑hydroxyprogesterone measured in the morning follicular phase screens for non‑classic congenital adrenal hyperplasia. 1
• Prolactin and TSH testing are required to exclude hyperprolactinemia and thyroid dysfunction. 1
• β‑hCG pregnancy test must be performed in any amenorrheic patient before initiating hormonal therapy. 1
• Fasting glucose/insulin ratio < 4.5 indicates insulin resistance. 1
• Lipid profile showing low HDL and elevated triglycerides is common in PCOS. 1

Diagnostic Imaging

• Pelvic ultrasound is mandatory to detect steroid‑cell ovarian tumors (≈ 0.2 % of hyperandrogenic women, > 50 % malignant) and to assess polycystic ovarian morphology and endometrial thickness. 1
• High‑resolution adrenal CT is indicated when testosterone ≥ 200 ng/dL, DHEAS > 6 600 ng/mL, or clinical suspicion of an adrenal source despite lower hormone levels. 1
• When adrenal carcinoma is suspected, a comprehensive serum androgen panel (DHEAS, testosterone, estradiol, 17‑OH‑progesterone, androstenedione, 17‑OH‑pregnenolone, 11‑deoxycortisol, progesterone) is recommended. 2

Therapeutic Interventions

Surgical

• Unilateral adrenalectomy is the treatment of choice for unilateral cortisol‑producing adrenal masses with clinically apparent Cushing syndrome; a minimally invasive approach is preferred. 2

Medical

• Low‑dose glucocorticoids (e.g., dexamethasone 0.25–0.5 mg nightly or prednisone 5–7.5 mg nightly) for 2–3 months can suppress adrenal‑dominant hyperandrogenism, with tapering after normalization and monitoring every 3–4 months for one year. 1
• Combined oral contraceptives are first‑line for PCOS‑related hyperandrogenism to regulate menses and suppress ovarian androgen production. 1
• Anti‑androgen therapy (e.g., spironolactone 50–200 mg/day) is indicated for persistent hirsutism; use is off‑label and contraindicated in pregnancy. 1
• Metformin 1500–2000 mg/day targets insulin resistance, especially in overweight patients with acanthosis nigricans. 1
• Cyclic progestins (e.g., medroxyprogesterone 10 mg for 10–14 days every 1–3 months) prevent endometrial hyperplasia when OCPs are contraindicated. 1

Prioritization in the Context of Continuous Cervical Mucus

• In patients with severe virilization, exclusion of an androgen‑secreting tumor takes precedence over treatment of continuous cervical mucus. 1

Follow‑up and Long‑Term Surveillance

• Initial 3‑month follow‑up should reassess androgen levels, cutaneous signs, and return of regular menses. 1
• Long‑term monitoring every 3–4 months for one year after therapy cessation to detect recurrence; annual metabolic screening (fasting glucose, lipids, blood pressure) for PCOS patients. 1
• Endometrial protection with progestin‑induced withdrawal bleeding at least every 3 months in amenorrheic patients to reduce endometrial cancer risk. 1

Clinical manifestations of hyperandrogenism

Cutaneous, menstrual, and metabolic effects

• Hyperandrogenism in women may present with cutaneous signs such as hirsutism, acne, and androgenic alopecia, menstrual disturbances, and metabolic abnormalities including dyslipidemia, hypertension, and impaired glucose tolerance, as reported by the American College of Endocrinology and the American Association of Clinical Endocrinology. 3

Urgent Evaluation and Clinical Features of Virilisation in Women

Epidemiology and Malignancy Risk

• The American College of Endocrinology (ACE) and the American Association of Clinical Endocrinologists (AACE) state that virilisation in women requires immediate assessment to rule out an androgen‑secreting tumor, because > 50 % of such tumors are malignant. 4

Clinical Manifestations of Virilisation

• Clitoromegaly is a hallmark sign of severe hyperandrogenism in women. 4
• Deepening of the voice is a characteristic manifestation of virilisation. 4
• Male‑pattern muscular development (increased upper‑body musculature) indicates significant androgen excess. 4
• Breast atrophy is frequently observed in women with virilisation. 4
• Male‑type alopecia (including bitemporal hair loss) is a common cutaneous sign of androgen excess. 4
• Severe hirsutism (excess terminal hair growth) is a key clinical feature of virilisation. 4
• Masculine habitus (overall male‑type body habitus) may develop with prolonged androgen exposure. 4

Rapid‑Onset Androgen Excess

• The ACE/AACE guidelines emphasize that a rapidly progressive androgen‑excess syndrome (developing over weeks to months) accompanied by oligomenorrhea or marked amenorrhea should immediately raise suspicion for a virilising condition. 4

Tumor Etiology (Priority Evaluation)

• Ovarian tumors – Leydig‑cell tumors and steroid‑cell tumors of the ovary are recognized androgen‑secreting neoplasms. 4
• Adrenal tumors – Functionally active adrenal adenomas or adrenal cortical carcinomas can produce excess androgens. 4

Non‑Tumor Etiology

• Ovarian hyperthecosis is associated with severe hyperandrogenism and concurrent insulin resistance. 4
• Non‑classic congenital adrenal hyperplasia is an endocrine disorder that can present with virilising features. 4

Exogenous Androgen Exposure

• Use of exogenous androgens—including anabolic‑steroid abuse (particularly in athletes) and the synthetic androgen danazol—can cause virilisation. 4

Medication‑Induced Androgen Elevation

• Valproic acid is the only anticonvulsant documented to increase serum testosterone levels, potentially contributing to virilisation. 5

Rapid Virilization in Women – Evidence‑Based Referral Guidelines

Urgent Referral Criteria (within days)

• Women who develop hyperandrogenic signs (e.g., deepening of voice, increased upper‑body muscle mass, clitoral enlargement) over a period of weeks to months should be referred immediately for endocrine and oncologic assessment because the rapid onset signals a high likelihood of an androgen‑secreting tumor. 6, 7
• If hyperandrogenic manifestations worsen despite standard medical therapy, urgent specialist evaluation is warranted to exclude a malignant source. 6, 7
• The presence of a palpable abdominal or pelvic mass on physical examination in a woman with hyperandrogenism mandates prompt referral for imaging and oncologic work‑up. 6, 8

Semi‑Urgent Referral Criteria (within weeks)

• A Ferriman‑Gallwey hirsutism score > 15 in a woman with suspected hyperandrogenism indicates moderate‑to‑severe hirsutism and should trigger a comprehensive endocrine work‑up. 6, 7, 8, 9
• Even a sudden onset of mild hirsutism, when recent, requires endocrine evaluation because rapid change may reflect an underlying tumor. 6, 7, 9
• Menstrual irregularities such as oligomenorrhea or amenorrhea accompanying hyperandrogenic signs are a red flag for endocrine pathology and merit specialist referral. 8
• Central obesity together with acanthosis nigricans suggests insulin resistance, which can coexist with androgen‑producing neoplasms and should prompt further endocrine assessment. 8
• Failure to achieve clinical improvement after 6–9 months of cosmetic, dermatologic, or oral‑contraceptive therapy indicates the need for re‑evaluation by an endocrinologist. 6, 8
• Worsening of hyperandrogenic symptoms while on treatment signals possible tumor progression and requires urgent endocrine reassessment. 6, 7

Critical Diagnostic Pitfalls to Avoid

• Moderate‑level androgen secretion can arise from indolent tumors that present with subtle signs; clinicians must not dismiss such cases as benign. 6, 7
• Always inquire about exogenous androgen exposure (e.g., anabolic steroids, danazol, valproic acid) because these can mimic tumor‑related virilization. 6, 7

Rationale for Urgent Referral

• Approximately 0.2 % of women with hyperandrogenism harbor an androgen‑secreting tumor, and more than 50 % of these tumors are malignant; therefore, rapid identification is essential. 9, 10
• Classic virilization signs (deep voice, clitoral enlargement, increased musculature) reflect massive androgen production and demand immediate endocrine investigation to prevent irreversible changes and to address potential malignancy. 6, 7